This site is intended for healthcare professionals

MHRA (UK) approves Evusheld to prevent Covid-19.-AstraZeneca

Read time: 1 mins
Published:18th Mar 2022

Evusheld (tixagevimab/cilgavimab) from AstraZeneca has been authorised for COVID-19 prevention by the Medicines and Healthcare products Regulatory Agency (MHRA) after meeting the UK regulatory standards of safety, quality and effectiveness.

The decision to grant approval for this treatment was endorsed by the government’s independent expert scientific advisory body, the Commission on Human Medicines, after carefully reviewing the evidence.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.